| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10576089 | MARIUS PHARMS LLC | Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols |
Dec, 2030
(6 years from now) | |
| US10576090 | MARIUS PHARMS LLC | Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols |
Dec, 2030
(6 years from now) | |
| US11590146 | MARIUS PHARMS LLC | Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols |
Dec, 2030
(6 years from now) | |
| US11617758 | MARIUS PHARMS LLC | Emulsion formulations |
Mar, 2033
(8 years from now) | |
Kyzatrex is owned by Marius Pharms Llc.
Kyzatrex contains Testosterone Undecanoate.
Kyzatrex has a total of 4 drug patents out of which 0 drug patents have expired.
Kyzatrex was authorised for market use on 27 July, 2022.
Kyzatrex is available in capsule;oral dosage forms.
Kyzatrex can be used as method of treating testosterone deficiency.
The generics of Kyzatrex are possible to be released after 15 March, 2033.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 27, 2025 |
Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient
Market Authorisation Date: 27 July, 2022
Treatment: Method of treating testosterone deficiency
Dosage: CAPSULE;ORAL
More Information on Dosage
KYZATREX family patents
